01/10/11 A couple days before the entry of the New Year, I watched the newly released movie “New Year’s Eve.” In both “NYE” scenarios, the celebrations were crazy and people were having a good time…just as they were last year, and the year before and long before that. People love to celebrate and New Year’s Eve is a perfect opportunity to do that – reflect on past resolutions and accomplishments and start fresh with a new slate of “this year I’m going to…” challenges.
Let’s consider that opportunity from a Kanzius Foundation perspective. One resolution, made over 40 years ago and carried forth year after year, was a declaration that America was going to wage war against cancer. This National Cancer Act was signed into law by Richard Nixon in 1971. On our website, Kanzius.org, we have a moving counter depicting the number of casualties in this war – to date nearly 24 million moms and brothers, co-workers and neighbors, loved ones and strangers. Why mention this? Why carry the declaration over to another year? Because new drugs and toxic treatments are NOT good enough.
The Kanzius Cancer Research Foundation may have joined the war late, yet recent research accomplishments are more worthy of reflection and celebration than any in years past. Most recently, we announced “the device is ready.” These four words signify what all of us hope: that this is the beginning of the end of invasive and debilitating cancer treatments like traditional chemo and radiation therapy. This device, a radio-frequency generator with greater capacity, will allow researchers to test the Kanzius Noninvasive Radiowave Cancer Treatment on larger, non-human subjects – and eventually, on people, if it works and is approved by the Food & Drug Administration (FDA). GenV, as it is called, is the fifth generation of the device which John Kanzius developed, and is being shipped to the Kanzius Labs at M.D. Anderson Cancer Center in Houston to begin testing.
The GenIV device has validated the killing of pancreatic cancer cells in small, non-human laboratory subjects without harming healthy, neighboring tissue. No one else can claim that! Dr. Steven Curley, the lead Kanzius researcher, has long stressed the importance of a device with greater capacity as it can accommodate larger human-like subjects and ultimately transition to humans.
The Kanzius Foundation added forces this past year to help intensify the fight. As John used to say, “Cancer does not discriminate…who or where you are, rich and poor alike.” In one month’s time, two new partners were, for the first time, used in the same sentence: Ellen DeGeneres and Glenn Beck. These two polarizing celebrities aided the Kanzius efforts to raise more than $100,000 in new donations. Additionally, last year more than 15,000 new Facebook fans and 6,000 Twitter followers began their journey to support “a better way to treat cancer” without side effects. Google granted the Kanzius Foundation $480,000 of free advertising, the Sunflower Club’s gift of $50,000 and over 10,000 new constituents, with gifts of all denominations, added to the global Team Kanzius.
2012 offers so many historical opportunities in the research lab and beyond. More than six validating articles are in a prepublication status. A tremendous amount of research must be completed but only increased revenue can make this possible. On January 15, we begin a four month competition for more than $200,000 in the Pinkwell Challenge Against Breast Cancer: Donate, Vote, Share! (For more information, visit Kanzius.org/Pinkwell) With this knowledge, we have a greater responsibility.
If we are going to declare that the war on cancer IS over, we need to believe, we need to resolve, we need to act… now.
MARK A. NEIDIG SR. is executive director of the Kanzius Cancer Research Foundation (MNeidig@Kanzius.org).